key: cord-0948141-gfq5vz0o authors: Kalita, Jayantee; Pandey, Prakash C; Shukla, Ruchi; Misra, Usha K title: Feasibility and usefulness of tele-follow-up in the patients with tuberculous meningitis date: 2021-05-24 journal: Trans R Soc Trop Med Hyg DOI: 10.1093/trstmh/trab069 sha: 6e1e8f9e3415e08de3d036d991637bd4e9b8d115 doc_id: 948141 cord_uid: gfq5vz0o BACKGROUND: Tuberculous meningitis (TBM) is the most severe form of tuberculosis and these patients need close follow-up because of a high frequency of complications. The coronavirus disease 2019 pandemic and lockdown resulted in an interruption in physical follow-up. In this situation, tele-follow-up may be helpful. We report the feasibility and usefulness of a telephonic follow-up in patients with TBM. METHODS: Patients with TBM managed by us from January 2017 to March 2020 were included from the TBM registry. Their presenting symptoms, and clinical and investigation findings were noted. We contacted these patients telephonically and their clinical status was obtained using a questionnaire. Based on the telephonic information, outcomes were categorized as death, poor or good. Patients with the new medical problems were advised as to relevant investigations and the reports were obtained through WhatsApp for prescribing treatment. RESULTS: The telephone numbers of 103 of 144 (71.5%) patients were viable. Twenty-seven (26.2%) patients died, 15 (19.7%) had a poor outcome and 61 (80.2%) had a good outcome. Twenty-five (32.9%) patients had new medical problems: 18 TBM related and 7 TBM unrelated. The medical problems of 23 patients could be managed telephonically and only 3 (4%) patients needed a physical visit. Sixty-five (85.5%) patients happily answered the questionnaire and willing responders needed a treatment modification more frequently than the reluctant responders (p=0.008). Patients on active antitubercular treatment needed treatment modification more frequently (80% vs 21.3%). CONCLUSIONS: Tele-follow-up is feasible in 96% of TBM patients and is beneficial, cost effective and overcomes the barrier of distance. Tuberculosis (TB) is a global health problem and its annual incidence is 110-165 cases/100 000 population in developing countries. 1 About 10% of TB is extrapulmonary and central nervous system (CNS) TB is the most severe form, resulting in high mortality (20-30%) and morbidity (56.1-78.5%). [1] [2] [3] The disease course in tuberculous meningitis (TBM) following treatment is unpredictable in the initial few months. About two-thirds of TBM patients develop complications during the antitubercular treatment (ATT), including drug-induced hepatitis, hydrocephalus, granuloma, infarction, seizure, visual loss, cerebral salt wasting and syndrome of inappropriate antidiuretic hormone secretion (SIADH). 4, 5 These complications usually occur within a few weeks to 6 months after initiation of treatment. 6, 7 It is not possible to keep these patients in the hospital for such a long time because of the limited health infrastructure, cost of hospitalisation and work loss of caregivers. In developing countries, repeat followup at closer intervals may not be possible and the dropout rate is higher. 8, 9 Moreover, the poor transportation system results in an interruption in follow-up, causing a treatment gap and complications. 10 During the coronavirus disease 2019 (COVID- 19) pandemic and lockdown in India, not only the COVID-19 infection resulted in suffering and deaths, but non-COVID patients also faced difficulties in physical consultations with their treating physicians. Many patients with TBM are bedridden and non-communicative, and there is restricted travel across the states. In this situation, tele-follow-up may be helpful in identifying and solving their problem and recording their outcome. In chronic diseases such as Alzheimer's disease, stroke, epilepsy and renal transplant, telemedicine has emerged as an alternative method of follow-up. 11, 12 There is no study evaluating the feasibility of telefollow-up in the management of CNS infection, especially in TBM. In this communication we report the feasibility and usefulness of tele-follow-up in a cohort of TBM patients. We also evaluated the variables of those patients needing a change in medication, investigation or readmission. This study was conducted in the Department of Neurology of a tertiary care teaching hospital in Lucknow, Uttar Pradesh, India. This hospital caters to patients from adjoining states, including Bihar, Madhya Pradesh, Chhattisgarh, West Bengal and Assam, as well as from the neighbouring country Nepal. The patients with TBM admitted to the neurology service under two investigators (JK and UKM) from 2017 to 2020 were included. The baseline details were obtained from a prospectively maintained TBM registry. The patients' phone numbers were retrieved from the hospital information source. Patients who died in the hospital were excluded. The diagnosis of TBM was based on the clinical history of meningitis illness (fever for >2 weeks, headaches, vomiting), cerebrospinal fluid pleocytosis with elevated protein and computed tomography/magnetic resonance imaging (MRI) findings (exudates, hydrocephalus, granuloma or infraction). The presence of Mycobacterium tuberculosis in cerebrospinal fluid culture or smear, positive polymerase chain reaction (PCR) or extra-CNS bacteriologically confirmed TB was considered definite TBM. The absence of bacteriological confirmation was grouped as probable TBM. 13 The baseline characteristics of the patients, including demographics (age, gender, residence), duration of illness, seizures, altered sensorium and focal neurological deficits were noted. The severity of TBM at admission was graded as per the modified Medical Research Council (MRC) criteria: 14, 15 stage I, meningitis only; stage II, meningitis with a focal deficit or Glasgow Coma Scale (GCS) score of 11-14; stage III, meningitis with a GCS score <11. Blood counts, erythrocyte sedimentation rate in the first hour, haemoglobin, blood glucose, blood urea nitrogen, serum creatinine, sodium, potassium, transaminases, bilirubin, albumin, calcium and alkaline phosphate were measured. Chest radiograph, electrocardiogram and human immunodeficiency virus serology were done. Cranial MRI was done using a 3T MRI machine (GE Medical System, Wauwatosa, WI, USA). T1, T2, fluid-attenuated inversion recovery, diffusion weighted imaging and T1 contrast images were obtained. The presence of exudate, hydrocephalus, infarction and tuberculoma was noted. Cerebrospinal fluid was analysed for cells, proteins, sugar, M. tuberculosis (smear and culture), polymerase chain reaction for M. tuberculosis and cryptococcal antigen. A four-drug ATT (rifampicin 10 mg/kg, ∼450 mg; isoniazid 5 mg/kg, ∼300 mg; ethambutol 15 mg/kg, ∼800 mg; pyrazinamide 25 mg/kg, ∼1500 mg daily) was prescribed. Prednisolone 40 mg/day was prescribed for 1 month then tapered over the next month. Aspirin 150 mg/day was also prescribed, except to those with coagulopathy, bleeding diathesis or peptic ulcer. Patients with seizures received levetiracetam and/or clobazam and those with hydrocephalus having features of elevated intracranial pressure had undergone ventriculoperitoneal shunt surgery. We generally practice physical follow-up and TBM patients are advised to return at 1, 3, 6, 12 and 18 months after discharge. During the lockdown, there was no public transport and routine outpatients services were closed; therefore we had to plan for tele-follow-up. A neurology resident (PCP) and a PhD student (RS) contacted the patients or their relatives telephonically under the supervision of a senior neurologist (JK). A questionnaire was used (Supplementary Table 1 ). The duration from the initiation of ATT to the telephone call was noted. The patients were asked about the continuation of prescribed drugs at discharge or previous physical follow-up, the occurrence of any complications during the COVID-19 pandemic and accessibility to medical consultation at our institute or a nearby hospital. If they had a medical problem, necessary investigations were advised and the reports were received through WhatsApp. The medical problems were managed by changing or starting new medication if possible. The patients with more severe or complicated problems, such as recurrence of meningitis symptoms, seizure, paralysis or altered sensorium, were advised to attend our hospital. The new motor deficit, movement disorder and outcome measures were confirmed by video call. Pre-recorded videos of seizures or movement disorders were accessed through WhatsApp. The outcome was assessed by the modified Rankin Scale (mRS) score and was categorized as death, poor (mRS >2-5) or good (mRS ≤2). For defining the outcome, the duration from the initiation of ATT to the day of the telephone call was considered. The normalcy of the continuous variable was assessed by the Wilk-Shapiro test. The telephonic response of the patient or caregiver was categorized into willing or reluctant groups. These two groups were compared in terms of age, gender, duration from the ATT to the phone call, sequalae and mRS score using χ 2 for categorical and independent t-test for continuous variables. The Wilcoxon ranked sign test was used for skewed data using Bonferroni correction. The above-mentioned parameters were also compared between the treatment beneficiary (needing dose modification, discontinuation or addition of a new drug) and nonbeneficiary (no change in treatment) groups. A variable with a two-tailed exact p-value <0.05 was considered significant. All the statistical analysis was done using the Statistical Package of Social Sciences version 20 software (IBM, Armonk, NY, USA). A total of 144 patients with TBM were admitted from January 2017 through March 2020. We started telephoning patients or their caregivers 6 months after the declaration of COVID-19 in India. The telephone numbers were not viable in 41 of 144 (28.5%) patients, therefore the information for 103 (71.5%) patients was collected. Thirty-two patients had definite and 71 had probable TBM. All the patients were literate and received a median of 12 y of schooling (range 4-17). Forty patients were urban dwellers and 36 rural. Twenty-nine patients and 47 caregivers responded to the questionnaire. Twenty-seven of 103 (26.2%) patients died a median of 24 months (range 6-36) after discharge from our hospital. The exact cause of death was unknown; however, caretakers stated that it was likely to be TBM related, because they had headaches, vomiting and altered sensorium. They died within 1 week of these symptoms without getting any medical treatment. The details of the patients are presented in Figure 1 . During the 6 months of the pandemic, one patient had a mild COVID-19 infection and none died of COVID. We generally prescribe 18 months of ATT to patients with TBM. Sixty-one patients completed 18 months of ATT at the time of the telephone call and 15 were still on ATT. Of the 76 surviving patients, medical problems were detected in 25 (32.9%): TBM related in 18 and TBM unrelated in 7 (oral ulceration in 1, excessive sleepiness in 2, arthralgia in 2, urinary tract infection in 1 and diabetes in 1). In the TBM-related cases, modification of ATT was needed in 12 patients, hepatotoxic drugs (isoniazid, pyrazinamide and rifampicin) were temporally withdrawn in 3 due to drug-induced hepatitis, an antiepileptic drug was added in 3 due to seizure recurrence and prednisolone was discontinued in 2 ( Table 1) . A total of 65 (85.5%) patients or caregivers happily shared their medical information: 26 of 29 (89.6%) patients and 39 of 47 (83%) caregivers (p=0.42). Fifteen (19.7%) patients in the willing group were on ATT. Eleven (14.6%) patients were reluctant to share their information and all had completed 18 months of ATT. All the patients on active ATT were willing to share information, whereas 11 (18%) in the ATT completed arm were reluctant to share information. Those patients needing treatment modification either in ATT or for other medical illnesses were willing (100% vs 0%), whereas 11 of 51 (21.56%) patients not needing treatment modification were reluctant to share information (p=0.008). The age, gender, residence, severity of meningitis at admission and neurological sequelae were not related to willingness ( Table 2 ). The telephone call resulted in treatment modification in 25 patients: TBM related in 18 and TBM unrelated in 7. The details are presented in Supplementary Table 2 . Patients on ATT needed treatment modification more frequently than those who com-pleted ATT (80.0% vs 21.3%; p=0.001). The treatment modification was mainly due to TBM or antitubercular drugs in the ATTcontinued group. In the ATT-completed group, medical advice was needed for osteoarthritis, diabetes, oral ulcer, urinary tract infection and seizures. The time from the ATT to the phone call was not related to the disability (p=0.72) and neurological deficit (p=0.56) but was related to treatment modification (Table 3) . were present in 15 (19.7%), a focal deficit in 4 (5.2%) and both in 12 (15.8%) patients. The stage of meningitis was related to outcome (p<0.001) but not to sequelae (p=0.20; Figure 2 ). The video call was done in three patients and investigations through What-sApp were accessed in three patients. Three (4%) patients had to visit our hospital: two due to altered sensorium and one due to refractory seizures. In this cohort of patients, the distance from the patients' residence to our hospital ranged from 18 to 1400 km. If we consider the cheapest mode of travel (train) for the patient and for one accompanying person, the cost of travel ranged from 100 to 2800 rupees (median 900 rupees). During lockdown, public transportation was not available and the use of private transport would have incurred a many-fold increase in travel costs. This study has revealed the feasibility and usefulness of telefollow-up of TBM patients after discharge from the hospital. About 33% of patients needed treatment modification and only 4% of patients needed to visit the hospital. All the patients shared the needed information; however, patients having medical problems or receiving ATT were happier to get the telephone call and shared information more willingly. We used a smartphone for video calls, which has helped in assessing patients in real time, especially those with jaundice, oedema, seizures and movement disorders. The smartphone also helps in the transfer of investigation reports or pre-recorded videos to the treating physician. In our cohort, WhatsApp messages helped to diagnose drug-induced hepatitis, seizure and outcome. Conventional telemedicine needs a large amount of equipment, bandwidth and manpower. Indians are the largest users of smartphones and WhatsApp. There are about 450 million smartphone and 400 million WhatsApp users in India. 16, 17 Smartphones can be used for both synchronous and asynchronous tele-followup. In the synchronous teleconference, the patient and physician interact in real time. In asynchronous telecare, information is stored, processed and evaluated later. 18 We have done real-time synchronous tele-follow-up in all patients, and in some patients stored video or investigations were transferred and analysed later; following which necessary treatment modification and advice were given. The feasibility of telecare has been evaluated in various neurological disorders such as stroke, epilepsy, Parkinson's disease, dementia and other chronic neurological disorders. 19, 20 However, tele-follow-up and telecare have not been applied in patients with CNS infections. CNS infections, including TBM, neurocysticercosis, pyogenic meningitis, scrub typhus, viral encephalitis and fungal infections, are prevalent in developing countries. [21] [22] [23] Patients with severe dengue, scrub typhus encephalitis, cerebral malaria and pyogenic meningitis need hospitalization, and surviving patients usually have a good recovery. 24, 25 On the other hand, 30-50% of patients with acute viral encephalitis have various neurological sequelae, including cognitive impairment, movement disorders, seizures and motor deficits. These patients could be followed up using various telecare modalities. The role of telemedicine has been evaluated in patients with active pulmonary and extrapulmonary TB. Almost all the studies revealed similar levels of treatment adherence for patients via telemedicine and those examined in person by a public health worker. [26] [27] [28] [29] In Papua New Guinea, a web-based 'store and forward' telemedicine service was used to optimize the treatment of multidrug-resistance TB. 30 In a study of patients with active pulmonary TB, videophone technology was used for directly observed therapy (DOT) of 304 treatment doses. It revealed 95% treatment adherence in a cost-effective manner. 26 Guo et al. 31 compared video DOT with DOT in person in 405 TB patients in each arm and reported comparable treatment adherence (96.1% vs 94.6%) and satisfaction. The video DOT group needed a shorter observed time per dose and incurred a lower cost. Patients with TBM require hospital care at the initial stage for investigations. The patients with hydrocephalous and deteriorating consciousness may require a ventriculoperitoneal shunt. During the initial few months of ATT, TBM patients may develop various complications, including hepatitis, infarction, hydrocephalus, spinal arachnoiditis, paradoxical tuberculoma, cerebral salt wasting and seizures. 32 Delayed sequelae (seizure, hydrocephalous and paraparesis), although uncommon, may occur as a result of fibrosis and adhesions. 33 In TBM, seizure as a sequela is five times more frequent in those with seizures in the acute stage compared with those without. 34 We could detect medical problems in 21.3% (13/61) patients who completed 18 months of ATT. In our cohort, about 30% of patients could not be contacted, as their telephone numbers were not viable. In India, telephonic follow-up studies of neurological patients have reported invalid phone numbers in 36.8% of patients. 35 Changing subscriber identity module (SIM) cards is a common practice in developing countries, especially in underprivileged areas. Often these people change SIM cards due to promotion strategies, low cost or extra features. 36 This study is retrospectively designed due to the needs of the hour-lockdown, closure of outpatient services and limited emergency admission for fear of COVID-19. The data for the patients included herein regarding diagnosis, treatment and clinical parameters were retrieved from a prospectively maintained TBM registry. A future prospective study may be undertaken to compare the efficacy and cost effectiveness of physical followup and tele-follow-up. Telephonic follow-up using a smartphone is feasible in patients with TBM and the majority of their medical problems could be sorted out. This might be a cost-and time-saving method for use in real-time physician-patient interactions. Authors' contributions: JK was involved in the concept, planning and formulation of the study, data interpretation and finalizing the manuscript. PCP was responsible for the management of patients, data collection and statistical analysis. RS was responsible for data collection and statistical analysis. UKM was responsible for patient management and supervision of the study. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic Prognosis of tuberculous meningitis in adults in the era of modern antituberculous chemotherapy Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis Hypovolemia due to cerebral salt wasting may contribute to stroke in tuberculous meningitis Traitement des tuberculoses cérébro-méningées Serial study of clinical and CT changes in tuberculous meningitis Isoniazid-associated hepatitis in 114 patients Tuberculosis treatment nonadherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review Guillain-Barré syndrome: subtypes and predictors of outcome from India Strengthening of primary health care: key to deliver inclusive health care Diagnostic and interventional implications of telemedicine in Alzheimer's disease and mild cognitive impairment: a literature review Telemedicine quality and outcomes in stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Role of oxidative stress in tuberculous meningitis: a clinico-radiological correlation Value of different staging systems for predicting neurological outcome in childhood tuberculous meningitis Inclusion of mechanical ventilation in severity staging of tuberculous meningitis improves outcome prediction Overall India handset market growth to fall in 2020 WhatsApp now has 400 million active users in India Telehealth systems. StatPearls Multidisciplinary approach and outcomes of tele-neurology: a review Telemedicine-guided education on secondary stroke and fall prevention following inpatient rehabilitation for Texas patients with stroke and their caregivers: a feasibility pilot study Tuberculous meningitis: more questions, still too few answers Tuberculous meningitis Scrub typhus meningitis in South India-a retrospective study Neurological manifestations of scrub typhus Spectrum and outcome of acute infectious encephalitis/encephalopathy in an intensive care unit from India The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project Tuberculosis therapy and telemedicine The use of videophone for directly observed therapy for the treatment of tuberculosis Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation Telemedicine in resource-limited settings to optimize care for multidrug-resistant tuberculosis Telemedicine technologies and tuberculosis management: a randomized controlled trial Complications of tuberculous meningitis and their effect on outcome in a tertiary care cohort Diagnosis & Management of Neurological Disorders Seizures in bacterial meningitis: prevalence, patterns, pathogenesis, and prognosis Connecting in COVID 19: neurology tele-follow-up experience India dumps the second SIM card with a vengeance, 60 mn numbers set to be history We thank Shakti Kumar for secretarial help. The corresponding author on behalf of other authors declares no conflict of interest in terms of any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications or opinions stated-including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition.Funding: This is an investigator initiated study. Ruchi Shukla got fellowship from Department of Science and Technology , India.Ethical approval: This study was approved by the institutional ethics committee of the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. The data are available upon reasonable request from RS and PCP.